Home Cart Sign in  
Chemical Structure| 62996-74-1 Chemical Structure| 62996-74-1

Structure of Staurosporine
CAS No.: 62996-74-1

Chemical Structure| 62996-74-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Staurosporine is a prototypical potent ATP-competitive multikinase inhibitor with IC50 of 0.7, 7, 8.5, 6, 20 nM for PKC, PKA,PKG, p60v-src tyrosine protein kinase, CaM kinase II, respectively.

Synonyms: STS; AM-2282; Staurosporin.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Staurosporine

CAS No. :62996-74-1
Formula : C28H26N4O3
M.W : 466.53
SMILES Code : C[C@]12[C@@](OC)([H])[C@@](NC)([H])C[C@](O2)([H])N3C4=CC=CC=C4C5=C6C(CN=C6O)=C7C8=CC=CC=C8N1C7=C53
Synonyms :
STS; AM-2282; Staurosporin.
MDL No. :MFCD18252446

Safety of Staurosporine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Staurosporine

epigenetics
GPCR

Isoform Comparison

Biological Activity

Target
  • PKCη

    PKCη, IC50:4 nM

  • PKCγ

    PKCγ, IC50:5 nM

  • PKCε

    PKCε, IC50:73 nM

  • PKCα

    PKCα, IC50:2 nM

  • PKCδ

    PKCδ, IC50:20 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
LLC1 mouse lung cancer cells 100 nM overnight As positive control for apoptosis assays PMC6952835
M13SV1, R2-2, R2-N1 0.5 µM 12 h Induction of apoptosis, results showed that the basal caspase activity of R2-2 and R2-N1 cells was higher than that of M13SV1 cells, and staurosporin-induced apoptosis was more pronounced in the two derivative cell lines. PMC4660649
astrocytes 100 nM 5 h To investigate the protective effect of Staurosporine on astrocytes against oxidative stress damage. The results showed that Staurosporine significantly inhibited the wound closure ability of astrocytes, but TX14(A) could restore their function. PMC6492175
LECs 4 µM 2 h As a positive control to induce apoptosis PMC7876020
HepG2 56 µM 1 day To evaluate the cytotoxicity of Staurosporine on HepG2 cells PMC5622171
HEK293 56 µM 1 day To evaluate the cytotoxicity of Staurosporine on HEK293 cells PMC5622171
Hepa 1-6 56 µM 1 day To evaluate the cytotoxicity of Staurosporine on Hepa 1-6 cells PMC5622171
CCM3−/− CI-huVECs 0.05 µM or 0.25 µM 2, 8, and 24 hours To assess the sensitivity of CCM3−/− CI-huVECs to apoptotic signals, results showed significantly reduced caspase-3 activity in mutant ECs. PMC9166869

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00651261 Leukemia Phase 3 Active, not recruiting - -
NCT01161550 Leukemia, Myeloid, Acute Phase 1 Completed - United States, Missouri ... More >> Washington University School of Medicine St. Louis, Missouri, United States, 63110 Less <<
NCT00019838 Leukemia Lymp... More >>homa Less << Phase 1 Completed - United States, Maryland ... More >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 Less <<
NCT00651261 - Active, not recruiting - -
NCT02115295 Leukemia Phase 2 Recruiting May 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less <<
NCT01754441 - Unknown December 2017 United States, Delaware ... More >> Alfred I. duPont Hospital for Children Wilmington, Delaware, United States, 19803 United States, Florida Nemours Children's Specialty Care, Jacksonville Jacksonville, Florida, United States, 32207 Nemours Children's Hospital Orlando, Florida, United States, 32827 Less <<
NCT03512197 Acute Myeloid Leukemia (AML) Phase 3 Recruiting April 20, 2026 -
NCT03092674 Acute Myeloid Leukemia ... More >> Myelodysplastic Syndrome Myelodysplastic Syndrome With Excess Blasts-2 Untreated Adult Acute Myeloid Leukemia Less << Phase 2 Phase 3 Suspended(Other - Safety data ... More >>review, unscheduled) Less << August 1, 2023 -
NCT03591510 FLT3-mutated Acute Myeloid Leu... More >>kemia Less << Phase 2 Not yet recruiting April 21, 2025 Korea, Republic of ... More >> Novartis Investigative Site Seoul, Korea, Republic of, 03080 Less <<
NCT00042861 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, Maryland ... More >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 Less <<
NCT00031681 Advanced Adult Primary Liver C... More >>ancer Carcinoma of the Appendix Estrogen Receptor-negative Breast Cancer Extensive Stage Small Cell Lung Cancer Gastrointestinal Stromal Tumor HER2-negative Breast Cancer Metastatic Gastrointestinal Carcinoid Tumor Ovarian Sarcoma Ovarian Stromal Cancer Progesterone Receptor-negative Breast Cancer Recurrent Adenoid Cystic Carcinoma of the Oral Cavity Recurrent Adult Primary Liver Cancer Recurrent Anal Cancer Recurrent Basal Cell Carcinoma of the Lip Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor Recurrent Breast Cancer Recurrent Cervical Cancer Recurrent Colon Cancer Recurrent Endometrial Carcinoma Recurrent Esophageal Cancer Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity Recurrent Extrahepatic Bile Duct Cancer Recurrent Gallbladder Cancer Recurrent Gastric Cancer Recurrent Gastrointestinal Carcinoid Tumor Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity Recurrent Lymphoepithelioma of the Nasopharynx Recurrent Lymphoepithelioma of the Oropharynx Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Recurrent Mucoepidermoid Carcinoma of the Oral Cavity Recurrent Non-small Cell Lung Cancer Recurrent Ovarian Epithelial Cancer Recurrent Ovarian Germ Cell Tumor Recurrent Pancreatic Cancer Recurrent Prostate Cancer Recurrent Rectal Cancer Recurrent Salivary Gland Cancer Recurrent Small Cell Lung Cancer Recurrent Small Intestine Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Nasopharynx Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral Cavity Small Intestine Adenocarcinoma Small Intestine Leiomyosarcoma Small Intestine Lymphoma Stage IV Adenoid Cystic Carcinoma of the Oral Cavity Stage IV Anal Cancer Stage IV Basal Cell Carcinoma of the Lip Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor Stage IV Breast Cancer Stage IV Colon Cancer Stage IV Endometrial Carcinoma Stage IV Esophageal Cancer Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity Stage IV Gastric Cancer Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity Stage IV Lymphoepithelioma of the Nasopharynx Stage IV Lymphoepithelioma of the Oropharynx Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Stage IV Mucoepidermoid Carcinoma of the Oral Cavity Stage IV Non-small Cell Lung Cancer Stage IV Ovarian Epithelial Cancer Stage IV Ovarian Germ Cell Tumor Stage IV Pancreatic Cancer Stage IV Prostate Cancer Stage IV Rectal Cancer Stage IV Salivary Gland Cancer Stage IV Squamous Cell Carcinoma of the Hypopharynx Stage IV Squamous Cell Carcinoma of the Larynx Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IV Squamous Cell Carcinoma of the Nasopharynx Stage IV Squamous Cell Carcinoma of the Oropharynx Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IV Verrucous Carcinoma of the Larynx Stage IV Verrucous Carcinoma of the Oral Cavity Stage IVA Cervical Cancer Stage IVB Cervical Cancer Triple-negative Breast Cancer Unresectable Extrahepatic Bile Duct Cancer Unresectable Gallbladder Cancer Unspecified Adult Solid Tumor, Protocol Specific Untreated Metastatic Squamous Neck Cancer With Occult Primary Less << Phase 1 Completed - United States, Virginia ... More >> University of Virginia Charlottesville, Virginia, United States, 22908 Less <<
NCT00045513 Leukemia Lymp... More >>homa Less << Phase 1 Phase 2 Completed - Canada, Ontario ... More >> McMaster Children's Hospital at Hamilton Health Sciences Hamilton, Ontario, Canada, L8N 3Z5 London Health Sciences Centre London, Ontario, Canada, N6A 465 Princess Margaret Hospital at University Health Network Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT00045942 - Completed - -
NCT00819546 Acute Myeloid Leukemia ... More >> Myelodysplastic Syndrome Less << Phase 1 Active, not recruiting December 2019 United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Less <<
NCT00047242 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, Maryland ... More >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231-2410 Less <<
NCT01477606 Acute Myeloid Leukemia Phase 2 Active, not recruiting June 2020 -
NCT03280030 Acute Myeloid Leukemia Phase 2 Recruiting June 20, 2022 Hong Kong ... More >> Novartis Investigative Site Recruiting Hong Kong, Hong Kong Japan Novartis Investigative Site Recruiting Nagoya-city, Aichi, Japan, 466-8650 Novartis Investigative Site Recruiting Toyoake city, Aichi, Japan, 470 1192 Novartis Investigative Site Recruiting Kashiwa, Chiba, Japan, 277-8577 Novartis Investigative Site Recruiting Matsuyama-city, Ehime, Japan, 790-8524 Novartis Investigative Site Recruiting Fukuoka city, Fukuoka, Japan, 812-8582 Novartis Investigative Site Recruiting Fukuyama city, Hiroshima, Japan, 720-0001 Novartis Investigative Site Recruiting Isehara-city, Kanagawa, Japan, 259-1193 Novartis Investigative Site Recruiting Kochi city, Kochi, Japan, 781-8555 Novartis Investigative Site Recruiting Nagasaki-city, Nagasaki, Japan, 852-8501 Novartis Investigative Site Recruiting Sayama, Osaka, Japan, 589 8511 Novartis Investigative Site Recruiting Shimotsuke city, Tochigi, Japan, 329-0498 Novartis Investigative Site Recruiting Bunkyo-ku, Tokyo, Japan, 113-8677 Novartis Investigative Site Recruiting Shinagawa-ku, Tokyo, Japan, 141 8625 Korea, Republic of Novartis Investigative Site Recruiting Seoul, Korea, Republic of, 03722 Taiwan Novartis Investigative Site Recruiting Putzu City, Chiayi Hsien, Taiwan, 61363 Novartis Investigative Site Recruiting Kaohsiung City, Taiwan, 83301 Novartis Investigative Site Recruiting Taipei, Taiwan, 10002 Novartis Investigative Site Recruiting Taoyuan, Taiwan, 33305 Less <<
NCT00093600 Acute Myeloid Leukemia (AML) Phase 1 Completed - United States, California ... More >> Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States, 90095-1781 United States, Massachusetts Dana Faber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201-2014 United States, Texas MD Anderson Cancer Center/University of Texas Houston, Texas, United States, 77030 Germany Novartis Investigative Site Dresden, Germany Novartis Investigative Site Mainz, Germany Less <<
NCT00045942 Acute Myeloid Leukemia ... More >> Myelodysplastic Syndromes Less << Phase 1 Phase 2 Completed - United States, California ... More >> UCLA Medical Center Los Angeles, California, United States, 90095 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York New York Weill Cornell Medical Center New York, New York, United States, 10021 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT03760445 Leukemia, Myeloid, Acute Phase 1 Phase 2 Not yet recruiting October 13, 2022 -
NCT00036777 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, Maryland ... More >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 Less <<
NCT01130662 Acute Myeloid Leukemia Phase 1 Completed - United States, Kansas ... More >> University of Kansas Medical Center, Westwood Campus Kansas City, Kansas, United States, 66205 Less <<
NCT00012194 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Terminated - United States, New Hampshire ... More >> Dartmouth Hitchcock Medical Center Lebanon, New Hampshire, United States, 03756 Less <<
NCT00045175 Fallopian Tube Cancer ... More >> Ovarian Cancer Primary Peritoneal Cavity Cancer Less << Phase 1 Completed - Canada, Ontario ... More >> Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT00039403 Adenocarcinoma of the Pancreas... More >> Recurrent Pancreatic Cancer Stage II Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Less << Phase 1 Completed - United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03258931 Newly Diagnosed FLT3 Mutated A... More >>ML Less << Phase 3 Recruiting November 2024 United States, California ... More >> US Davis Health Recruiting Sacramento, California, United States, 95817 Contact: Brian Jonas, MD    800-282-3284    bajonas@ucdavis.edu    United States, Florida Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Kendra Sweet, MD    813-745-6841    Kendra.Sweet@moffitt.org    United States, Kansas University of Kansas Recruiting Kansas City, Kansas, United States, 66160 Contact: Sunil Abhyankar, MD    913-588-9281    sabhyankar@kumc.edu    United States, Massachusetts Dana-Farber Cancer Insitute Recruiting Boston, Massachusetts, United States, 02215 Contact: Richard M Stone, MD    617-632-2214    Richard_Stone@dfci.harvard.edu    United States, Michigan Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Jay Yang, MD    800-527-6266    yangj@karmanos.org    Henry Ford Health System Recruiting Detroit, Michigan, United States, 48202 Contact: Yue Guo, MD    800-436-7936    YGUO1@hfhs.org    United States, New York Roswell PArk Recruiting Buffalo, New York, United States, 14263 Contact: Eunice S Wang, MD    716-845-3544    eunice.wang@roswellpark.org Less <<
NCT00045500 Lymphoma Unsp... More >>ecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Completed - United States, Maryland ... More >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 Frederick Cancer Research and Development Center Frederick, Maryland, United States, 21702-1201 Less <<
NCT00006464 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, California ... More >> USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California, United States, 90033-0804 City of Hope Medical Group Pasadena, California, United States, 91105 University of California Davis Cancer Center Sacramento, California, United States, 95817 United States, New Hampshire Norris Cotton Cancer Center Lebanon, New Hampshire, United States, 03756-0002 Less <<
NCT00045747 Pancreatic Cancer Phase 2 Completed - United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Less <<
NCT00004059 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Less <<
NCT00072267 Fallopian Tube Cancer ... More >> Ovarian Cancer Primary Peritoneal Cavity Cancer Less << Phase 2 Completed - Canada, Ontario ... More >> Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Ottawa Regional Cancer Centre Ottawa, Ontario, Canada, K1H 8L6 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT00098956 Extensive Stage Small Cell Lun... More >>g Cancer Recurrent Small Cell Lung Cancer Less << Phase 2 Completed - Canada, Ontario ... More >> Princess Margaret Hospital Phase 2 Consortium Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT00098956 - Completed - -
NCT03207334 Acute Myeloid Leukemia Phase 2 Withdrawn(Insufficient funding... More >>) Less << January 2022 United States, Florida ... More >> University of Florida Gainesville, Florida, United States, 32610 Less <<
NCT01202877 - Completed - -
NCT00030888 Kidney Cancer Phase 2 Unknown - United States, California ... More >> UCSF Comprehensive Cancer Center San Francisco, California, United States, 94115 Veterans Affairs Medical Center - San Francisco San Francisco, California, United States, 94121 Less <<
NCT00004263 Leukemia Myel... More >>odysplastic Syndromes Less << Phase 1 Completed - United States, Ohio ... More >> Arthur G. James Cancer Hospital - Ohio State University Columbus, Ohio, United States, 43210 United States, Texas University of Texas - MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00072189 Recurrent Melanoma ... More >> Stage IV Melanoma Less << Phase 2 Terminated(Early termination f... More >>or discouraging results) Less << - United States, California ... More >> UC Davis Cancer Center Sacramento, California, United States, 95817 Less <<
NCT01174888 Acute Myeloid Leukemia ... More >> Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Less << Phase 1 Completed - United States, Ohio ... More >> The Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less <<
NCT00072189 - Terminated(Early termination f... More >>or discouraging results) Less << - -
NCT00082017 Lymphoma, Large-Cell, Ki-1 ... More >> Lymphoma, T-Cell Less << Phase 2 Terminated(IND was withdrawn b... More >>y CTEP due to low accrual and cost of maintaining the IND.) Less << - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00233454 Systemic Mastocytosis, Aggress... More >>ive (ASM) Leukemia, Mast Cell Hematological Non-mast Cell Lineage Disease (AHNMD) Less << Phase 2 Completed - United States, California ... More >> Stanford University School of Medicine Stanford, California, United States, 94305 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Missouri Washington University-St. Louis Saint Louis, Missouri, United States, 63110 Less <<
NCT01202877 Leukemia Phase 1 Phase 2 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00003289 Leukemia Lymp... More >>homa Unspecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Completed - United States, Maryland ... More >> Johns Hopkins Oncology Center Baltimore, Maryland, United States, 21231 Less <<
NCT00301938 Accelerated Phase Chronic Myel... More >>ogenous Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Acute Promyelocytic Leukemia (M3) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Blastic Phase Chronic Myelogenous Leukemia Myelodysplastic/Myeloproliferative Neoplasms Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Relapsing Chronic Myelogenous Leukemia Secondary Acute Myeloid Leukemia T-cell Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Myeloid Leukemia Less << Phase 1 Completed - United States, Maryland ... More >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 Less <<
NCT00782067 Leukemia Phase 2 Completed - -
NCT00782067 - Completed - -
NCT01282502 Adenocarcinoma of the Rectum Phase 1 Completed - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less <<
NCT00082017 - Terminated(IND was withdrawn b... More >>y CTEP due to low accrual and cost of maintaining the IND.) Less << - -
NCT00866281 Acute Myeloid Leukemia ... More >> Acute Lymphoblastic Leukemia Less << Phase 1 Phase 2 Terminated(Despite considerabl... More >>e efforts to boost recruitment during the final year of the study, no new patients were enrolled.) Less << - United States, Washington ... More >> Seattle Children's Hospital CPKC412A2114 Seattle, Washington, United States, 98105 France Novartis Investigative Site Paris Cedex 19, France, 75935 Italy Novartis Investigative Site Genova, GE, Italy, 16147 Novartis Investigative Site Monza, MB, Italy, 20900 Novartis Investigative Site Roma, RM, Italy, 00165 Novartis Investigative Site Torino, TO, Italy, 10126 Netherlands Novartis Investigative Site Rotterdam, Netherlands, 3015 GJ Sweden Novartis Investigative Site Stockholm, Sweden, SE-171 76 Less <<
NCT00866281 - Terminated(Despite considerabl... More >>e efforts to boost recruitment during the final year of the study, no new patients were enrolled.) Less << - -
NCT01830361 Acute Myeloid Leukemia Phase 2 Active, not recruiting September 2020 Germany ... More >> Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III Chemnitz, Germany Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I Dresden, Germany Marien Hospital Düsseldorf, Germany Universitätsklinikum Erlangen, Medizinische Klinik 5 Erlangen, Germany Klinikum der Johann-Wolfgang-Goethe Universität Frankfurt Main, Germany Universitätsklinikum Heidelberg Heidelberg, Germany Universitätsklinikum Jena, Klinik für Innere Medizin II Jena, Germany Universitätsklinikum Gießen und Marburg GmbH Marburg, Germany Universitätsklinikum Münster Münster, Germany Städtisches Klinikum Nord Nürnberg, Germany Klinikum der Universität Regensburg Regensburg, Germany Less <<
NCT01883362 Acute Myeloid Leukemia Phase 2 Completed - -
NCT01429337 Hepatic Impairment Phase 1 Recruiting August 14, 2019 United States, Texas ... More >> Novartis Investigator site Not yet recruiting Houston, Texas, United States, 77030 Novartis Investigator site Not yet recruiting San Antonio, Texas, United States, 78215 Belgium Novartis Investigative Site Terminated Bruxelles, Belgium, 1200 Bulgaria Novartis Investigative Site Recruiting Sofia, Bulgaria, 1618 Germany Novartis Investigative Site Terminated Berlin, Germany, 14050 Novartis Investigative Site Terminated Frankfurt, Germany, 60590 Lithuania Novartis Investigator site Not yet recruiting Kaunas, Lithuania, LT-50161 Poland Novartis Investigative Site Terminated Warszawa, Poland, 02 106 Romania Novartis Investigative Site Recruiting Cluj, Napoca, Romania, 400006 Less <<
NCT02078609 AML and High Risk MDS Phase 1 Recruiting September 3, 2019 United States, Michigan ... More >> Novartis Investigative Site Recruiting Ann Arbor, Michigan, United States, +1 48109 0944 Contact: Sabrina Pelton Hargrove    +1 734 936 8538    sgomes@med.umich.edu    Principal Investigator: Dale Bixby          United States, Texas Novartis Investigative Site Recruiting Houston, Texas, United States, 77030 Australia, Victoria Novartis Investigative Site Recruiting Prahran, Victoria, Australia, 3181 France Novartis Investigative Site Completed Marseille, France, 13273 Germany Novartis Investigative Site Completed Ulm, Germany, 89081 Italy Novartis Investigative Site Recruiting Milano, MI, Italy, 20132 Novartis Investigative Site Recruiting Milano, MI, Italy, 20162 Novartis Investigative Site Recruiting Roma, RM, Italy, 00133 Japan Novartis Investigative Site Recruiting Shinagawa-ku, Tokyo, Japan, 141 8625 Netherlands Novartis Investigative Site Recruiting Amsterdam, Netherlands, 1081 HV Less <<
NCT01920204 Indolent Systemic Mastocytosis Phase 2 Unknown May 2015 Netherlands ... More >> University Medical Center Groningen Groningen, Netherlands, 9700RB Less <<
NCT02634827 Acute Myeloid Leukemia With FL... More >>T3/ITD Mutation Acute Myeloid Leukemia With Gene Mutations FLT3 Tyrosine Kinase Domain Point Mutation Secondary Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia Less << Phase 2 Active, not recruiting April 15, 2020 United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT03114228 - - - Canada, Ontario ... More >> Novartis Investigative Site Hamilton, Ontario, Canada, L8V 1C3 Canada, Quebec Novartis Investigative Site Montreal, Quebec, Canada, H1T 2M4 Less <<
NCT00233454 - Completed - -
NCT03686345 Core Binding Factor Acute Myel... More >>oid Leukemia (CBF-AML) Less << Phase 2 Active, not recruiting December 31, 2025 Italy ... More >> Ospedale Cà Granda - Niguarda S.C: Ematologia Milano, Italy, 20162 Less <<
NCT02723435 Acute Myeloid Leukemia With Ge... More >>ne Mutations Adult Acute Myeloid Leukemia in Remission Less << Phase 2 Withdrawn(Logistical and admin... More >>istrative issues) Less << - -
NCT02624570 - - - -
NCT03379727 Acute Myeloid Leukemia Phase 3 Recruiting December 30, 2021 -
NCT00001444 Breast Cancer ... More >> Lymphoma Neoplasm Prostatic Neoplasm Less << Phase 1 Completed - United States, Maryland ... More >> National Cancer Institute (NCI) Bethesda, Maryland, United States, 20892 Less <<
NCT01846624 Acute Myeloid Leukemia (AML) W... More >>ith Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults AML (Adult) With 11q23 (MLL) Abnormalities AML (Adult) With Del (5q) AML (Adult) With Inv (16) (p13; q22) AML (Adult) With t (16;16) (p13; q22) AML (Adult) With t (8; 21) (q22; q22) Secondary AML (Adult) Untreated AML (Adult) Less << Phase 2 Terminated(Accrual factor) - United States, California ... More >> Stanford University School of Medicine Stanford, California, United States, 94305 Less <<
NCT01846624 - Terminated(Accrual factor) - -
NCT01093573 Untreated Adult Acute Myeloid ... More >>Leukemia Less << Phase 1 Phase 2 Unknown - United States, Ohio ... More >> Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106 United States, West Virginia West Virginia University Morgantown, West Virginia, United States, 26506 Less <<
NCT03582800 Systemic Sclerosis|Dermatomyos... More >>itis|iPPSD2 Less << PHASE2 RECRUITING 2025-06-06 CHU de BORDEAUX, Bordeaux, 330... More >>00, France|Hospice Civil de Lyon, Bron, 69500, France|ApHp - H?pital Bicêtre, Le Kremlin-Bicêtre, 94270, France|CHU de Limoges, Limoges, 87042, France|ApHp - h?pital Lariboisière, Paris, 75000, France|CHU de ROUEN, Rouen, 76031, France|CHU de Toulouse, Toulouse, 31000, France Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.14mL

0.43mL

0.21mL

10.72mL

2.14mL

1.07mL

21.43mL

4.29mL

2.14mL

References

 

Historical Records

Categories